Oncology, Immunology/Inflammation and Ophthalmology
Dr. Per Gjörstrup serves as Medical Scientific Advisor at TFS since 2013 in the inflammation and oncology therapeutic areas where he specializes in protocol design and development plans.
Dr. Gjörstrup has more than 25 years’ experience of research and development in the pharmaceutical and biotechnology industry, most recently as co-founder and Chief Scientific and Medical Officer at Resolvyx Pharmaceuticals Inc., a Cambridge, MA based biopharmaceutical Company. Prior to this, Dr. Gjörstrup held senior management roles at Micromet Inc., Schwartz Pharma, Biogen (Biogen Idec), Pharmacia (Pfizer) and Astra (AstraZeneca) from 1982-2005.
Dr. Gjörstrup is an expert in translational medicine and led seven first-in-man therapies, in inflammation and oncology, through phase I, early phase II, and with some continuing into phase III, and later approval. He has extensive experience in optimizing preclinic-to-clinic strategies, interacting with regulatory agencies, patent strategies, fund raising and partnership building. He has continued to publish extensively in leading scientific journals and is the holder of issued patents.
Dr. Gjörstrup is adjunct associate professor at SUNY College of Optometry, New York, affiliated with "The Center for Experimental Therapeutics and Reperfusion Injury" at Brigham and Women's Hospital, Boston, and also a member of the MIT List Center Advisory Committee. He currently is the CEO of Anida Pharma Inc.